Magnetar Financial LLC Buys Shares of 47,804 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Magnetar Financial LLC bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 47,804 shares of the company’s stock, valued at approximately $379,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in Amneal Pharmaceuticals by 149.7% in the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock valued at $10,792,000 after purchasing an additional 777,568 shares during the last quarter. Barclays PLC grew its stake in shares of Amneal Pharmaceuticals by 134.1% during the third quarter. Barclays PLC now owns 296,384 shares of the company’s stock worth $2,466,000 after acquiring an additional 169,756 shares during the last quarter. State Street Corp grew its stake in shares of Amneal Pharmaceuticals by 3.8% during the third quarter. State Street Corp now owns 3,514,721 shares of the company’s stock worth $29,242,000 after acquiring an additional 127,753 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth about $520,000. Finally, Geode Capital Management LLC grew its stake in shares of Amneal Pharmaceuticals by 11.1% during the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock worth $31,511,000 after acquiring an additional 378,136 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Down 3.9 %

Shares of NASDAQ AMRX opened at $8.66 on Friday. The business’s 50 day moving average price is $8.38 and its 200 day moving average price is $8.37. The firm has a market cap of $2.68 billion, a P/E ratio of -12.74 and a beta of 1.05. Amneal Pharmaceuticals, Inc. has a 52 week low of $5.18 and a 52 week high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The firm had revenue of $730.52 million during the quarter, compared to analysts’ expectations of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same quarter in the prior year, the company earned $0.14 EPS. As a group, research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Barclays boosted their price target on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, March 3rd. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Finally, StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $10.80.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the transaction, the insider now directly owns 48,578,209 shares of the company’s stock, valued at approximately $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gautam Patel sold 17,410 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total value of $139,454.10. Following the transaction, the director now directly owns 2,031,476 shares of the company’s stock, valued at approximately $16,272,122.76. The trade was a 0.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,240,000 shares of company stock valued at $43,754,000. 26.56% of the stock is owned by company insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.